The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Shares of Nordic Nanovector quadruple on high volumes in four days before profit taking took over, after it announced a definitive share exchange agreement to combine with Thor Medical, a fellow Norway-based privately held company focused on the production of alpha-emitting radionuclides for cancer treatment, in an all-share transaction. 10 June 2023
San Diego, USA-base next-gen gene therapy developer Kate Therapeutics (KateTx) has emerged from stealth mode with a $51 million Series A financing. 9 June 2023
In mid-2014, the Kingdom of Saudi Arabia (KSA) faced one of the most daunting economic development challenges of its modern history, when crude oil prices collapsed by more than half. 9 June 2023
The Windsor Framework sets out a long-term solution for the supply of medicines into Northern Ireland as part of the revized agreement relating to the UK’s Brexit. 9 June 2023
The US Food and Drug Administration (FDA) has accepted the Biologics License Applications (BLAs) for the investigational treatment exagamglogene autotemcel (exa-cel) for severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) that has been submitted by US biotech Vertex Pharmaceutical. 9 June 2023
Sandoz, the generics and biosimilars unit of Novartis, has outlined an ambitious plan for its newly-independent future once the spin-out from its parent is complete. 9 June 2023
The US Food and Drug Administration (FDA) has published guidance entitled Clinical Drug Interactions Studies with Combined Oral Contraceptives. 9 June 2023
Anglo-Swedish pharma major AstraZeneca has entered into a collaboration, exclusive option and license agreement with privately-held UK biopharma Quell Therapeutics. 9 June 2023
With evolving patient pathways, advances in technology and surges of new data, traditional commercial models have been disrupted, and the expectations and preferences of healthcare providers (HCPs) have changed. 9 June 2023
Danish allergy expert ALK Abello (ALKB: DC) has reported positive Phase III results from a trial of its sublingual allergy immunotherapy tablet for the treatment of allergic rhinitis in children. 9 June 2023
The US Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) yesterday voted unanimously 21 to 0 that nirsevimab has a favorable benefit risk profile for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in new-borns and infants born during or entering their first RSV season. 9 June 2023
German radiopharmaceutical biotech ITM Isotope Technologies has announced an equity investment round of 255 million euros ($273 million) led by Temasek. 9 June 2023
Russian pharmaceutical companies will receive additional subsidies from the state for the development of analogues of foreign drugs, as part of the current state plans for the reduction of import dependence in the country’s pharmaceutical sector, The Pharma Letter’s local correspondent reports. 9 June 2023
Privately-held US firms Aviko Radiopharmaceuticals and Neutron Therapeutics have announced the formation of a strategic partnership to advance boron neutron capture therapy (BNCT) to treat cancer. 8 June 2023
The Indian government is exploring the possibility of introducing a Production Linked Incentive (PLI) scheme for basic chemicals and active pharmaceutical ingredients (API) industries. 8 June 2023
The number of medicines recalled by manufacturers due to defects has increased 153% in the UK since 2017, according to new figures from the Medicines and Healthcare products Regulatory Agency (MHRA), with relaxed regulations during Covid one possible factor behind the increase. 8 June 2023
Californian biopharma FibroGen suffered a setback in part of its development of pamrevlumab, sending its shares 11% lower in Wednesday’s trading. 8 June 2023
Israeli generics giant Teva Pharmaceutical Industries said today that its US subsidiary has fully resolved its nationwide settlement agreement related to opioid claims. 8 June 2023
South Korean contract development and manufacturing organization (CDMO) Samsung Biologics today revealed it has entered another strategic partnership with US pharma giant Pfizer (NYSE: PFE). 8 June 2023